Aromatase Inhibitor

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerHot FlashesOverall SurvivalDuctal Carcinoma in SituBatten Disease

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

Aromatase Inhibitor

Pfizer

Phase 3

232

Lexiscan

Astellas

Preclinical

13

Voltaren

Novartis

Preclinical

14

Methylthioninium Chloride

PProvepharm SAS

Preclinical

35

Tricor

JJagotec

Preclinical

16

Tianeptine

Pfizer

Preclinical

17

Ablavar

LLantheus Medical Imaging

Preclinical

28

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

19

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

110

Naltrexone/bupropion

Novo Nordisk

Preclinical

1Show 22 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Breast Cancer23 trials

Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer

Completed·SSun Yat-sen University·Phase 3·NCT02767661·263 enrolled

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Active, not recruiting·MMarina N Sharifi·Phase 2·NCT04762979·44 enrolled

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Active, not recruiting·Pfizer··NCT06495164·1 enrolled

Show 20 more trials

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Terminated·TTvardi Therapeutics, Incorporated·Phase 1·NCT05384119·6 enrolled

Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer

Completed·XXichun Hu·Phase 2·NCT01654185·60 enrolled

Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer

Withdrawn·BBritish Columbia Cancer Agency·Phase 2·NCT01814865

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

Completed·Roche·Phase 2·NCT01491737·258 enrolled

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

Completed·—·Phase 2·NCT03477396·2 enrolled

Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University··NCT05801705·700 enrolled

Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone

Completed·Pfizer··NCT05012644·197 enrolled

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Completed·AstraZeneca·Phase 2·NCT01446159·188 enrolled

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT06107673·144 enrolled

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

Completed·Roche·Phase 2·NCT00773695·150 enrolled

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Terminated·GSK·Phase 2·NCT01220128·66 enrolled

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT07400523·446 enrolled

Dendritic Cell Based Therapy for Breast Cancer Patients

Withdrawn·IInge Marie Svane·Phase 2·NCT00935558

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Completed·Novartis·Phase 3·NCT01160211·369 enrolled

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Completed·—·Phase 2·NCT02040857·162 enrolled

Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer

Unknown status·XXu fei·Phase 2·NCT02910050·58 enrolled

Efficacy and Safety of QL1706 Combined With Neoadjuvant Endocrine Therapy in Patients With HR-Positive/HER2-Negative Breast Cancer Showing a Poor Response to Neoadjuvant Chemotherapy: A Prospective, Randomized Controlled Clinical Trial

Not yet recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT07782840·40 enrolled

Clinical Trial to Evaluate Safety and Anti-tumor Activity of AKT Inhibitor, Ipatasertib,With Endocrine Therapy With/Without CDK 4/6 Inhibitor for Patients With Metastatic Hormone Receptor Positive Breast Cancer (TAKTIC)

Active, not recruiting·MMassachusetts General Hospital·Phase 1·NCT03959891·77 enrolled

A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75202, Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors

Recruiting·BBeOne Medicines·Phase 1·NCT07222267·86 enrolled

EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers

Active, not recruiting·Eli Lilly·Phase 1·NCT04188548·379 enrolled

Short stature1 trial

Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature

Completed·NNemours Children's Clinic·Phase 3·NCT01248416·76 enrolled

Absorption1 trial

Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?

Completed·UUniversity of Wisconsin, Madison·Phase 4·NCT00766532·12 enrolled

Frozen Embryo Transfer1 trial

The Outcome of Two Protocols Used to Prepare Endometrium for Frozen Embryo Transfer

Completed·RRahem Fertility Center·Phase 4·NCT04507022·112 enrolled

Overall Survival1 trial

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Completed·Pfizer··NCT06086340·779 enrolled

9 more indications

Genetic Polymorphism1 trial

CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)

Unknown status·KKorea University Anam Hospital··NCT00973505·100 enrolled

Effectiveness1 trial

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

Completed·Pfizer··NCT05361655·2,888 enrolled

Abemaciclib1 trial

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

Withdrawn·—·Phase 1·NCT03846583

First-line Treatment1 trial

Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT03910712·250 enrolled

Hormone-receptor-positive Breast Cancer1 trial

Neoadjuvant Culmerciclib Combined With Endocrine Therapy Versus Endocrine Therapy Alone for Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: a Single-center, Open-label, Randomized-controlled Phase II Clinical Trial

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07796880·80 enrolled

Ductal Carcinoma in Situ1 trial

A Clinical Study of a Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Recruiting·FFinn, Olivera, PhD·Phase 1·NCT06218303·50 enrolled

Metastatic Breast Cancer1 trial

European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies Assessed in a Real-World Non-Interventional Study (EUCHARIS)

Completed·Pfizer··NCT05043506·1,939 enrolled

Hot flashes1 trial

A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women With Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy

Active, not recruiting·Astellas·Phase 3·NCT06440967·982 enrolled

Batten Disease1 trial

GENEr8-2: Cerliponase alfa Earlier Intervention

Recruiting·BioMarin Pharmaceutical·Phase 2·NCT05700006·30 enrolled

Details

Drug Info

Related News